Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows 280.7% year over year
Q1 FY2026 selling, general & admin of $1.28M rose 280.7% year over year. Sequentially, it rose 264.4% from the prior quarter.
Context
- Selling, general & admin increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +0.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.28M+264.4% QoQ
- Last fiscal yearDec 2025
- $1.56M+0.9% YoY
- LTMMar 2026
- $2.5M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +280.7% | -100.0% | -380.7 pp |
| 1 year | +0.9% | -100.0% | -100.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 1.56M USD
- Year-over-year change
- +0.9%
- 2-year CAGR
- +24.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.56M | +0.9% |
| FY2024 | 2024-12-31 | 1.54M | +52.6% |
| FY2023 | 2023-12-31 | 1.01M | — |
Selling, General & Admin vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's LTM Mar 2026 selling, general & admin of $2.5M is the lowest of the 8 companies compared; the peer median is $26.89M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $52.9M | +705.9% | +168.0% | 191.0% | |
| LTM Mar 2026 | $40.64M | -22.7% | -27.3% | 131109.7% | |
| LTM Mar 2026 | $29.66M | +100.0% | +10.0% | 249.6% | |
| LTM Mar 2026 | $26.89M | -3.6% | -3.6% | 95.3% | |
| LTM Mar 2026 | $24.44M | +68.3% | +12.0% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $15.32M | -41.8% | +90.0% | — |
| LTM Mar 2026 | $13.3M | -6.8% | +1.5% | — | |
PLYXPolaryx Therapeutics, Inc. Common Stock | LTM Mar 2026 | $2.5M | — | — | — |
| Peer median (excluding PLYX) | $26.89M | -3.6% | +10.0% | 220.3% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 2.77M | 2.81M | 6.27M |
| Selling, General & Admin | 1.01M | 1.54M | 1.56M |
| Operating Expenses | 3.78M | 4.35M | 7.82M |
| Depreciation & Amortization | 0 | 0 | 0 |
| EBITDA | (3.78M) | (30.36M) | (8.99M) |
| EBITDA Margin | — | — | — |
| Operating Income | (3.78M) | (4.35M) | (7.82M) |
| Operating Margin | — | — | — |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2K | (26M) | (1.16M) |
| Income Before Tax | (3.78M) | (30.36M) | (8.99M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.02) | (0.16) | (0.19) |
| EPS (Diluted) | (0.02) | (0.16) | (0.19) |
| Weighted Avg Shares | 189.37M | 189.37M | 47.34M |
| Weighted Avg Shares (Diluted) | 189.37M | 189.37M | 47.34M |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.